Janice Burke

DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY.

Picchio Pharma, Inc. engages in acquiring, developing, and commercializing new therapeutic products and technologies. The company was founded in 2001 and is headquartered in Laval, Canada.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada.

CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada.

CFA Society Toronto supports the professional and business development of charterholders. It provides member services including educational programs, sponsored events, employment postings, and networking opportunities. The company was founded in 1936 and is headquartered in Toronto, Canada.

CTI Life Sciences Fund LP invests in high quality emerging life sciences companies located in Canada. The fund targets companies operating in the fields of pharmaceuticals and biotechnology companies. It provides financing for seed, early and development stage capital requirements. It also act as lead investor.

The Public Health Research Institute Center provides biomedical research. The private company is based in Newark, NJ.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.

BioAxone Therapeutic, Inc. provides an experimental therapy for the treatment of neurological disorders. The company was founded in April 2000 by Pierre Caouette and Lisa Mckerracher and is headquartered in Montreal, Canada.

BioTalent Canada is a non-profit organization, which focuses on building partnerships and skills for Canada?s bio-economy to ensure the industry has access to job-ready people. It connects employers with job seekers, delivers human resource information, and skills development tools so the biotech industry through projects, research and product development .The company is headquartered in Ottawa, Canada.

The Prince Edward Island BioAlliance, Inc. operates as a research institute. The company is headquartered in Charlottetown, Canada.

BioVectra, Inc. manufactures and supplies custom active pharmaceutical ingredients to the North American and European markets. It offers specialty and fine chemicals, advanced intermediates, enzymes and biomolecules, as well as provide custom synthesis and manufacturing services for the pharmaceutical, biopharmaceutical, and nutraceutical industries. The company was founded by Regis J. Duffy in 1970 and is headquartered in Charlottetown, Canada.

Innovative Medicines Canada manufactures medical and toilet products. The company was founded on April 23, 1914 and is headquartered in Ottawa, Canada.

Accel-Rx provides seed and start-up investment services to the new health sciences companies. It engages in leveraging investment support to the research and commercialization centers such as the existing health-related Centers of Excellence for Commercialization and Research (CECRs). The company was founded by Natalie Dakers in 2014 and is headquartered in Vancouver, Canada.

Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann.

FB Dermatology Ltd. is a med-tech company, which focuses on developing and exploring patented bio-photonic technology using fluorescent light energy to stimulate the skin’s own biological processes and repair mechanisms. Its products include Kleresca acne treatment, Kleresca skin rejuvenation, Kleresca rosacea treatment, and Kleresca pre-post Treasureratment. The company is headquartered in Dublin, Ireland.

Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada.

Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada.

Zucara Therapeutics, Inc. develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people. The company is headquartered in Toronto, Canada.